Even though US physicians are heeding the call to offer angiotensin-converting enzyme (ACE) inhibitors to more patients with myocardial infarction (MI), the drugs remain underprescribed.
A new study has examined data on diagnoses and prescriptions at discharge for 200000 patients with MI who were treated at 1400 US hospitals between 1994 and 1996. The report, by researchers at the University of California, San Francisco, School of Medicine, showed that ACE inhibitor prescriptions rose to 38.7% in 1996 from 25% in 1994. But the researchers said only half of patients who could have benefited most from the drug—those with congestive heart failure—received it. The study is in this month's Journal of the American College of Cardiology.
Voelker R. No ACE Up Their Sleeve. JAMA. 1998;280(8):687. doi:10.1001/jama.280.8.687-JQU80005-5-1